摘要
环原黄杨碱A(CPB-A)1～4mg/kg(1/100～1/25LD_(50))能防治BaCl_(12)、乌头碱和氯仿所致的实验性心律失常。在等毒性剂量下,CPB-A的抗心律失常怍用与环维黄杨星D(CVB-D)及胺碘达隆相似。但CPB-A的治疗指数(LD_(50)/ED_(50))是CVB-D的1.8倍,Amio的1.2倍。CPB-A 0.3～30μmol/L对心室肌电生理最显著的影响是延长APD_(50)、APD_(90)和ERP,这可能是其抗心律失常作用的重要机理,并提示它属于Ⅲ类抗心律失常药。灌流相同浓度(3μmol/L)时,CPB-A延长APD和ERP的作用比CVB-D和胺碘达隆均强。
Cycloprotobuxine A (CPB-A) l-4mg/kg (l/100-l/25LD50) produced therapeutic and prophylactic effects on experimental arrhythmias induced by BaCl2, aconi-tine and chloroform, which were dose-dependent. Equitoxic doses given, the antiar-rhythmic action of CPB-A was as potent as cyclovirobuxine D (CVB-D) and amioda-rone (Amio), however, its therapeutic index (LD50/ED50) was 1.8 times as many as that of CVB-D and 1.2 times as many that of Amio. The most pronounced effect of CPB-A (0.3-30μmol/L ) on the electrophysiology of ventricular muscle of guinea pig was the lengthening of APD50 APD90 and ERP. This character might contribute to its antiarrhythmic action and we suggest that CPB-A is most likely to belong to classⅢ antiarrhythmic drugs (prolongation of APD). Superfused with the same concentration (3 μmol/L), CPB-A brought about more significant increases in APD50, APD90 and ERP than that in CVB-D and Amio.
出处
《第四军医大学学报》
1989年第6期394-397,共4页
Journal of the Fourth Military Medical University
关键词
抗心律失常药
环原黄杨碱A
药理
antiarrhythmia agents
action potentials
cycloprotobuxine A
cyclovirobuxine D
amiodarone
